BioInvent International
10.12.2021 13:18:53 CET | ACCESS Newswire | Press release
LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), China's medical product regulator, has approved a Clinical Trial Application (CTA) submitted by BioInvent's licensee in China, CASI Pharmaceuticals (CASI). The CTA is for the initiation of two clinical trials of BioInvent's novel anti-FcyRIIB antibody, BI-1206, in patients with non-Hodgkin's Lymphoma (NHL) in China.
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. One is evaluating the BI-1206 combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors, and the other in combination with rituximab for the treatment of non-Hodgkin's lymphoma.
CASI is planning Phase 1 trials of BI-1206 as a single agent with the aim to evaluate the PK profile and in combination with rituximab in NHL (mantle cell lymphoma, marginal zone lymphoma and follicular lymphoma) to assess safety and tolerability, select the Recommended Phase 2 Dose and assess early signs of clinical efficacy as part of its development program for BI-1206 in China and associated markets. The studies are expected to start in H1 2022.
BioInvent and CASI have an exclusive licensing agreement for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong and Macau in both liquid and solid cancers, with CASI responsible for commercialization in China and associated markets. BioInvent is eligible to receive up to $83 million in development and commercial milestone payments plus tiered royalties in the high-single to mid-double-digit range on net sales of BI-1206.
"We are very pleased to see the first fruit of our development collaboration with CASI on BI-1206. As BioInvent develops the drug candidate across Europe and the US, our partnership with CASI focusing on China, Hong Kong, Macau and Taiwan, adds significant shareholder value to the company. Our expanding pipeline of first-in-class immunotherapies creates multiple development and commercial opportunities for the company and its partners." said Martin Welschof, CEO of BioInvent.
"We are excited to be able to accelerate the development of BI-1206 in China and contribute to its global development. The collaboration has been open, fast, efficient and professional. We believe BI-1206 has great potential to improve NHL treatment in China and elsewhere." said Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. ("CASI China"), which is located in Beijing, China. The Company has built a commercial team of over 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com .
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/676974/BioInvent-and-CASI-Pharmaceuticals-Announce-CTA-Approval-for-Clinical-Studies-of-BI-1206-in-NHL-in-China
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Announces Auditor Review of Q2 Financial Statements26.10.2026 21:30:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / October 26, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that, as of October 22, 2026, the Company's auditor, Manning Elliott LLP, has completed a review of the Company's second quarter consolidated interim financial statements for the six-month period ended July 31, 2026 (the "Financial Statements"), which were included in the Company's management information circular dated October 14, 2026, in connection with the Company's upcoming annual general and special meeting scheduled for November 13, 2026. No amendments were made to the Financial Statements as a result of the auditor's review, other than the removal of the "Notice of No Auditor Review." Upcoming Annual General and Special Meeting of Shareholders Additionally, Clean Air Metals' shareholders are reminded that the Annual General and Special Meeting of Shareholders (the "Meeting") will be held virtually on November 13, 2026. S
Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 202626.10.2026 15:00:00 CET | Press release
MIAMI, FL / ACCESS Newswire / October 26, 2026 / Miami Fashion Week® (MIAFW) celebrated its landmark 10th anniversary October 13-18, 2026, bringing together international designers, Latin American talent and Miami's creative community for six days of runway presentations, industry programming and special events. The milestone edition celebrated a decade of connecting Miami with the international fashion industry while continuing to expand beyond the runway through sustainability, technology, education and cultural exchange. Further strengthening its ties to the local community, MIAFW established a long-term partnership with Miami Dade College and Miami Fashion Institute. Images: Courtesy of Miami Fashion Week "Celebrating 10 years of Miami Fashion Week is an incredibly meaningful milestone," said Lourdes Fernandez-Velasco, Executive Director of Miami Fashion Week. "Over the past decade, we've built a platform that connects designers, creatives and industry leaders from around the world
Chervon Names Parker Wesley Clary Director of Field Sales - Southern Division26.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 26, 2026 / Parker Wesley Clary joins Chervon as Director of Field Sales - Southern Division, effective October 26, 2026, reporting to Thomas Kentouris, VP of Field Sales. Clary assumes responsibility for the Southern Division of the Chervon Field Sales Team. He is charged with developing a strong organization, building outstanding store-level merchandising and promotional programs. Most recently, Parker was a Key Account Manager for TTI/Milwaukee Pro Tools responsible for the Transportation Maintenance Vertical. His impressive career also includes a series of increasingly responsible positions in store coverage and field sales management. "Parker's exceptional sales and sales management skills will help us deliver our bold growth targets," said Thomas Kentouris. "He is a high-potential talent with a bright future ahead at Chervon." "The opportunity to be a part of Chervon's inspired high-performance culture was most compelling to me," said Par
Chervon names Joel Petersheim as Vice President, End User Research and Sales - OPE Commercial USA26.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 26, 2026 / Joel Petersheim joins Chervon as Vice President, End User Research and Sales - OPE Commercial, effective October 26, 2026, reporting to Joe Galli, CEO. Petersheim brings to Chervon 15+ years of experience at TTI/Milwaukee encompassing a series of increasingly responsible positions in sales, key account management, end user marketing, and sales management. Most recently, he held the position of Vice President Industrial Channel Sales - Northeast. Joel's impressive career also includes a series of director level end user marketing leadership roles focused on the MEP Verticals. His track record in converting key end users and in growing sales in each of his past positions was consistently outstanding. "Joel is a tremendous addition to the outstanding leadership team we are building at Chervon," said Joe Galli. "He is a high potential talent with a tremendous track record of success at the account and end user level." "I am enormously i
Chervon Names Maggie Jones Director of National Field Sales OPS26.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 26, 2026 / Maggie Jones joins Chervon as Director of National Field Sales Operations, effective October 26, 2026, reporting to Thomas Kentouris, VP of Field Sales. Jones will be charged with building out the support system, technology platform, and rigorous measurement/control process for the Chervon Field Sales Network. Most recently, Maggie was Divisional Sales Manager for TTI/Milwaukee where she was responsible for leading 140 field sales store coverage reps. She was an outstanding performer managing the high growth Texas region. Her career also included a series of store coverage and sales management positions in the Southeast USA. "Maggie is best described as an overachieving superstar," said Thomas Kentouris. "Her leadership skills, organization skills, and results orientation will serve her well as she builds our field sales team infrastructure." "I cannot wait to get started supporting Chervon's vision of industry leadership," said Jon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom